RecruitingNCT05139706

Montreal Immune-Related Adverse Events (MIRAE) Study

Montreal Database and Biorepository of Cancer Patients Treated With Immune Checkpoint Inhibitors for the Study of Immune-related Adverse Events

Sponsor

Sir Mortimer B. Davis - Jewish General Hospital

Enrollment

1,000 participants

Start Date

Jan 21, 2020

Study Type

OBSERVATIONAL

Conditions

Cancer Autoimmune Diseases Immune System Disorder Inflammatory Reaction

Summary

Immune checkpoint inhibitors (ICI) are among the most promising approaches to fighting cancer. However, a substantial percentage of patients experience off-target adverse effects in the form of mild to severe inflammation in different organs, commonly called immune-related adverse events (irAEs). irAEs can lead to treatment discontinuation, or can be life-threatening in extreme cases. The causes of irAEs are largely unknown and there are no reliable predictive biomarkers. The Montreal Immune-Related Adverse Events (MIRAE) study collects clinical information and biospecimens (blood, tissue, stool) from cancer patients treated with ICI to facilitate research on the identification of predictive biomarkers of irAEs, their causes, and the design of effective management strategies.

Eligibility

Min Age: 18 YearsMax Age: 100 Years

Plain Language Summary

Simplified for easier understanding

This study collects samples and data from people who experience immune-related side effects from cancer immunotherapy (checkpoint inhibitors), to better understand and eventually prevent these reactions. **You may be eligible if...** - You are 18 or older - You are a cancer patient who has received or is receiving immunotherapy (such as anti-PD-1, anti-PD-L1, or anti-CTLA-4 drugs) - OR you have an autoimmune condition that resembles an immunotherapy side effect - OR you are a healthy volunteer without cancer or inflammatory disease **You may NOT be eligible if...** - You are unable to provide informed consent Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.